The latest column from Ted Slafsky, publisher and CEO of 340B Report, addresses the likeliest path forward for 340B federal legislation.

COLUMN: After 340B Hearing and New Bills Emerging; The Likely Path Forward

Despite its importance, the 340B drug discount program rarely ever goes under the Congressional spotlight.  In fact, until the June [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at